MARKET

SLDB

SLDB

Solid Bioscience
NASDAQ
5.90
0.00
0.00%
After Hours: 6.08 +0.18 +3.05% 15:36 12/24 EST
OPEN
5.83
PREV CLOSE
5.90
HIGH
6.07
LOW
5.83
VOLUME
282.55K
TURNOVER
--
52 WEEK HIGH
7.37
52 WEEK LOW
2.410
MARKET CAP
459.67M
P/E (TTM)
-2.3662
1D
5D
1M
3M
1Y
5Y
1D
These Are the Most and Least Likely Biotech Takeover Targets for 2026
TipRanks · 1d ago
Here are the most and least likely M&A targets in biotech, according to Truist
Seeking Alpha · 1d ago
Weekly Report: what happened at SLDB last week (1215-1219)?
Weekly Report · 2d ago
Biotech Momentum Carries After-Hours Trading Gains
NASDAQ · 12/18 04:15
Solid Biosciences announces Duchenne muscular dystrophy added to HHS RUSP
TipRanks · 12/16 22:01
HHS adds Duchenne muscular dystrophy to recommended screening panel
TipRanks · 12/16 16:30
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
Barchart · 12/16 15:51
Solid Biosciences: Promising Gene Therapy Advancements and Strategic Pipeline Progress Drive Buy Rating
TipRanks · 12/15 14:15
More
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Webull offers Solid Biosciences Inc stock information, including NASDAQ: SLDB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLDB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLDB stock methods without spending real money on the virtual paper trading platform.